XWM
MRNA icon

Xcel Wealth Management’s Moderna MRNA Stock Holding History

Xcel Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,193
Closed -$388K – 124
2023
Q2 		$388K Sell
3,193
-20
-0.6% -$2.67K 0.12% 99
2023
Q1 		$493K Buy
3,213
+147
+5% +$24.3K 0.17% 86
2022
Q4 		$551K Buy
3,066
+50
+2% +$8.18K 0.22% 76
2022
Q3 		$357K Buy
3,016
+640
+27% +$97.1K 0.13% 93
2022
Q2 		$339K Sell
2,376
-900
-27% -$129K 0.12% 95
2022
Q1 		$564K Sell
3,276
-2,435
-43% -$410K 0.15% 89
2021
Q4 		$1.45M Buy
5,711
+48
+0.8% +$14K 0.37% 66
2021
Q3 		$2.18M Buy
5,663
+902
+19% +$333K 0.63% 47
2021
Q2 		$1.12M Buy
4,761
+281
+6% +$50.2K 0.34% 61
2021
Q1 		$587K Buy
+4,480
New +$649K 0.21% 79

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Xcel Wealth Management's MRNA Position: Q3 2023 in Review

Xcel Wealth Management sold out of Moderna (MRNA) in Q3 2023, closing a stake of 3,193 shares — an estimated $388K sold.

Xcel Wealth Management first reported a position in MRNA in Q1 2021 and held it in 10 quarters. The position peaked at $2.18M in Q3 2021. 889 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.

  • Xcel Wealth Management reported no remaining Moderna position as of Q3 2023 after selling out during the quarter.
  • Xcel Wealth Management sold 3,193 Moderna shares in Q3 2023, an estimated $388K.
  • Xcel Wealth Management first reported a position in Moderna in Q1 2021 and held it in 10 quarters.
  • Xcel Wealth Management's Moderna position peaked at $2.18M in Q3 2021.
  • 889 funds tracked by Wall St. Rank held Moderna as of Q3 2023.

Based on Xcel Wealth Management's 13F filing for Q3 2023, filed 17 Oct 2023.